Modality
Degrader
MOA
EZH2i
Target
WEE1
Pathway
mTOR
LN
Development Pipeline
Preclinical
~Dec 2018
→ ~Mar 2020
Phase 1
~Jun 2020
→ ~Sep 2021
Phase 2
~Dec 2021
→ ~Mar 2023
Phase 3
~Jun 2023
→ ~Sep 2024
NDA/BLA
Dec 2024
→ Aug 2028
NDA/BLACurrent
NCT04717128
1,316 pts·LN
2025-04→2025-05·Not yet recruiting
NCT03412442
2,829 pts·LN
2024-12→2028-08·Recruiting
4,145 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-05-2410mo agoPh3 Readout· LN
2028-08-022.3y awayPh3 Readout· LN
Trial Timeline
2025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-05-24 · 10mo ago
LN
Ph3 Readout
2028-08-02 · 2.3y away
LN
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04717128 | NDA/BLA | LN | Not yet recr... | 1316 | MRD |
| NCT03412442 | NDA/BLA | LN | Recruiting | 2829 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 | |
| Sovarasimod | Halozyme | Phase 1/2 | WEE1 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 |